isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl ester | 92964-08-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl ester
• 英文别名: (2-acetyl-3,5-dimethoxyphenyl) pyridine-4-carboxylate
• CAS: 92964-08-4
• 化学式: C₁₆H₁₅NO₅
• 分子量: 301.299
• InChiKey: KKCNGHAWGPSRGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  74.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl ester 在 硫酸 、 potassium hydroxide 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 5,7-dimethoxy-2-(pyridin-4'-yl)-4H-chromen-4-one
  参考文献：
  名称：

  Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors

  摘要：

  By inspiration of good Akt1 inhibitory and cytotoxic activity of our previously screened hits 1 and 2, a series of novel benzopyrans 3a–c, 4 and phenylpyrazoles 5a–c, 6a–b, and 7 were designed, synthesized, and biologically evaluated for their in vitro Akt1 inhibitory and cytotoxic activity. The results revealed that all of these compounds showed moderate‐to‐excellent antiproliferative effects against the tested cancer cell lines (i.e. HL‐60, OVCAR, PC‐3, and HepG2). Among them, compounds 3a and 3c exhibited preferable Akt1 inhibitory activities (IC50 of 3a and 3c are 6.18 and 5.28 μm, respectively), while compounds 4, 5a–c, 6a–b, and 7 only showed weak Akt1 inhibitory activities. Consequently, we used molecular docking and dynamic simulation to propose a mode of binding between Akt1 and the 3c compound.

  DOI：

  10.1111/cbdd.12489
• 作为产物：
  描述：

  异烟酸 、 2-羟基-4,6-二甲氧基苯乙酮 在 吡啶 、 三氯氧磷 作用下， 反应 16.0h， 以86%的产率得到isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl ester
  参考文献：
  名称：

  WO2007/16525

  摘要：

  公开号：

文献信息

• Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices
  申请人：Wong Norman C.W.

  公开号：US20090029987A1

  公开（公告）日：2009-01-29

  The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

  本发明涉及一种类似于多酚化合物，可用于抑制哺乳动物中VCAM-1表达、MCP-1表达和/或SMC增殖。所披露的化合物可用于调节炎症状态的标志物，包括血管炎症，并用于治疗和预防炎症和心血管疾病及相关疾病状态。
• Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
  申请人：Wong Norman C. W.

  公开号：US08410109B2

  公开（公告）日：2013-04-02

  The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

  本发明涉及一种类似多酚的化合物，可用于抑制哺乳动物中VCAM-1表达、MCP-1表达和/或SMC增殖。所述化合物可用于调节炎症状况的标志物，包括血管炎症，并用于治疗和预防炎症和心血管疾病及相关疾病状态。
• WO2007/16525
  申请人：——

  公开号：——

  公开（公告）日：——
• PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES
  申请人：RESVERLOGIX CORP.

  公开号：EP1909788A2

  公开（公告）日：2008-04-16
• US8410109B2
  申请人：——

  公开号：US8410109B2

  公开（公告）日：2013-04-02